



# ASH21 abstracts: What's hot in GvHD?



Brought to you by SES



**Scientific Education Support**

Supporters



 **NOVARTIS**

 **Kadmon**

**Syndax** 



To help navigate the exciting content being presented at the ASH21, the GvHD Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in GvHD, including prevention, treatment, novel approaches, and outcomes.



**Click**  
the abstracts  
to view

Prevention of GvHD after allogeneic hematopoietic cell transplantation	
<b>97</b>	<a href="#"><u>Single HLA Class I Mismatches with High Peptide Divergence in the Graft-Versus-Host Direction Are Associated with Inferior Survival after 9/10 HLA-Matched UD-HCT: A Retrospective Study from the CIBMTR</u></a>
<b>99</b>	<a href="#"><u>Randomized Trial of Tacrolimus and Methotrexate Versus Tacrolimus, Reduced Dose Methotrexate, and Mycophenolate Mofetil for Prevention of Graft-Versus-Host Disease after Myeloablative Related and Unrelated Donor Allogeneic Hematopoietic Cell Transplantation</u></a>
<b>100</b>	<a href="#"><u>A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation</u></a>
<b>102</b>	<a href="#"><u>Role of Extracorporeal Photopheresis in Prevention of Graft-Versus-Host Disease in Patients Treated with Allogeneic Hematopoietic Stem Cell Transplantation: A Randomized Controlled Trial</u></a>
Novel Approaches and Outcomes	
<b>169</b>	<a href="#"><u>A Phase II Study of Ruxolitinib Pre-, during- and Post-Hematopoietic Cell transplantation for Patients with Primary or Secondary Myelofibrosis</u></a>
<b>174</b>	<a href="#"><u>Haploidentical Vs. Matched Unrelated Donor Transplants Using Post-Transplant Cyclophosphamide for Lymphoma: A Joint CIBMTR/EBMT Study</u></a>
Treatment of acute and chronic GvHD	
<b>260</b>	<a href="#"><u>Mesenchymal Stromal Cells Plus Anti-CD25 Antibody and Calcineurin Inhibitors for Steroid-Resistant Acute Graft-Versus-Host Disease: A Multicenter, Randomized, Phase 3 Trial</u></a>
<b>261</b>	<a href="#"><u>Phase 2 Results of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor As Treatment for Life-Threatening Acute Gvhd</u></a>
<b>262</b>	<a href="#"><u>Pooled Allogenic Fecal Microbiotherapy MaaT013 for the Treatment of Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Phase IIa Heracles Study and Expanded Access</u></a>
<b>263</b>	<a href="#"><u>Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment</u></a>
<b>264</b>	<a href="#"><u>Phase II Clinical Trial of Abatacept for Steroid-Refractory Chronic Graft Versus Host Disease</u></a>



Potential Factors Affecting Outcomes of Variable Transplant Settings	
<b>912</b>	<a href="#"><u>Superior Outcomes with Fludarabine-Busulfan (Flu/Bu) Based Conditioning for Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis - a Comparative Analysis By CIBMTR</u></a>
Posters	
<b>3898</b>	<a href="#"><u>Belumosudil for Patients with Chronic Graft-Versus-Host Disease: Combined Analysis of Failure-Free Survival (FFS) in the KD025-208 and Pivotal Rockstar Trials</u></a>
<b>3904</b>	<a href="#"><u>Use of Belimumab for Prophylaxis of Chronic Graft-Versus-Host Disease</u></a>
<b>3909</b>	<a href="#"><u>Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT)</u></a>
<b>1809</b>	<a href="#"><u>Validating a Machine Learning Grading System for Acute Gvhd. a Study on Behalf of the EBMT Transplant Complications Working Party</u></a>
<b>2884</b>	<a href="#"><u>Management of Steroid-Refractory Graft-Versus-Host Disease – a Survey By the Transplant Complications Working Party of the EBMT</u></a>
<b>3890</b>	<a href="#"><u>Post-Transplant Cyclophosphamide in Acute Leukemia Patients Receiving More Than 5/10 HLA-Mismatched Allogeneic Stem Cell Transplantation: A Study on Behalf of the ALWP of the EBMT</u></a>





Follow us on Twitter to keep up  
to date with the latest from the  
ASH 2021!

**@gvhd\_hub**  
**#ASH21**  
**gvhdhub.com**